Utility of risk stratification for paclitaxel hypersensitivity reactions
The Journal of Allergy and Clinical Immunology: In Practice Oct 07, 2017
Otani IM, et al. - Hypersensitivity reactions (HSRs) are a common impediment to paclitaxel therapy. In this current study, utility and safety of risk stratification on the basis of severity of the initial HSR was assessed and, it was found that patients received paclitaxel safely as a result of implementing a management strategy using the initial HSR severity for risk stratification.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
